Prevalence, Incidence and Predictors of Severe Anaemia with Zidovudine-Containing Regimens in African Adults With HIV Infection within the DART trial

Simple item page
dc.contributor.authorSsali, Francis
dc.contributor.authorMunderi, Paula
dc.contributor.authorWalker, Sarah
dc.contributor.authorMugyenyi, Peter
dc.date.accessioned2023-02-06T16:52:19Z
dc.date.available2023-02-06T16:52:19Z
dc.date.issued2006
dc.description.abstractTo describe the prevalence, incidence and predictors of severe anaemia in previously untreated symptomatic HIV-infected adults with CD4+ T-cells <200 cells/mm3 initiating zidovudine-containing regimens in Africa. DART is a randomized trial comparing two strategies for HIV/AIDS management in Uganda and Zimbabwe.We analysed the occurrence of anaemia at weeks 4 and 12, and then every 12 weeks. We also evaluated sex, age, WHO stage, body mass index (BMI), baseline laboratory measurements and first regimen aspredictors of developing grade 4 anaemia (<6.5 mg/dl) by week 48 using logistic regression. To May 2005, 3,314 participants (65% women, 23% at WHO stage 4, median age=37 years, baseline CD4+ T-cell=86 cells/mm3 and median baseline haemoglobin=11.4 g/dl) had a median 72 weeks follow-up. Prevalence of grade 4 anaemia was 0.7%, 2.0%, 0.5% and <0.5% at weeks 4, 12, 24 and ≥36, respectively. Overall, 219 (6.6%) participants developed grade 4 anaemia by week 48; women and those with lower haemoglobin, CD4+ T-cell count and BMI at baseline were at significantly higher risk (P<0.05), but not those with lower neutrophils or receiving cotrimoxazole at baseline. We observed a higher incidence of grade 4 anaemia than in studies from industrialized countries, which is likely to be due in part to population characteristics and in part to a higher rate of concurrent HIV-related clinical events. Clinical vigilance and haemoglobin measurements 4, 8 and 12 weeks after starting zidovudine could help to manage serious anaemia.en_US
dc.identifier.citationSsali, F., Stöhr, W., Munderi, P., Reid, A., Walker, A. S., Gibb, D. M., ... & Gilks, C. F. (2006). Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. doi/10.1177/135965350601100612therapy, 11(6), 741-750.en_US
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/7592
dc.language.isoenen_US
dc.publisherAntiviral therapyen_US
dc.subjectDARTen_US
dc.subjectAnaemiaen_US
dc.subjectHIVen_US
dc.titlePrevalence, Incidence and Predictors of Severe Anaemia with Zidovudine-Containing Regimens in African Adults With HIV Infection within the DART trialen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Prevalence, incidence and predictors of severe anaemia.pdf
Size:
524.26 KB
Format:
Adobe Portable Document Format
Description:
Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences